Topical Timolol Administration Reduces the Incidence of Glaucomatous Damage in Ocular Hypertensive Individuals: A Randomized, Double-Masked, Long-Term Clinical Trial

Michael A. Kass, Bernard Becker, Mark R. Hoff, John M. Parkinson, Allan E. Kolker, William M. Hart, Mae O. Gordon

Research output: Contribution to journalArticlepeer-review

146 Scopus citations

Abstract

We conducted a randomized, double-masked, long-term clinical trial to determine whether topical timolol therapy was effective in delaying or preventing the onset of glaucomatous damage in moderate-risk ocular hypertensive subjects. In 62 patients, one eye was chosen randomly to receive timolol therapy twice daily while the fellow eye received placebo. During the course of the study, the mean ± SD difference in intraocular pressure between the timolol-treated and the placebo-treated eyes was 2.3 ± 2.6 mm Hg. Reproducible visual field loss developed in 4 timolol-treated eyes and 10 placebo-treated eyes. Progressive optic disc cupping was noted in 4 timolol-treated and 8 placebotreated eyes. Using a computerized image analysis system, the mean ± SD increase in optic disc pallor during the course of the study was 0.86% ± 2.4% in the timolol-treated eyes as opposed to 1.80% ± 3.6% in the placebo-treated eyes. This study provides evidence that lowering intraocular pressure by medical treatment reduces the incidence of glaucomatous damage in ocular-hypertensive individuals.

Original languageEnglish
Pages (from-to)1590-1598
Number of pages9
JournalArchives of Ophthalmology
Volume107
Issue number11
DOIs
StatePublished - Nov 1989

Fingerprint

Dive into the research topics of 'Topical Timolol Administration Reduces the Incidence of Glaucomatous Damage in Ocular Hypertensive Individuals: A Randomized, Double-Masked, Long-Term Clinical Trial'. Together they form a unique fingerprint.

Cite this